Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Germ Cell and Embryonal 1Medulloblastoma 1Glioma 1Breast Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × Mannitol × Clear all
NCT06768268 2025-04-16

ICGMV

National Taiwan University Hospital

Phase 1/2 Enrolling by invitation
30 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡